SelectMDx is a novel urine-based risk score, which combines urinary biomarkers homeobox C6 (HOXC6) and distal-less homeobox 1 (DLX1) with traditional clinical factors such as age, PSA, digital rectal examination (DRE), prostate volume, and family history of PCa to assess the probability of risk of suffering clinical significant PCa (Gleason score ≥ 7 or Grade group ≥ 2) [17–19]. This evidence concerns the gene DLX1 and posterior cortical atrophy.